[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572828":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":51,"collaborators":11,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Roma La Sapienza","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Test group","EXPERIMENTAL",null,[13],"Other: CHX 0.09% + Citrox + HA",{"label":15,"type":16,"description":11,"interventionNames":17},"Control group","ACTIVE_COMPARATOR",[18],"Drug: CHX 0.12%",[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"CHX 0.09% + Citrox + HA","The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.",[9],{"type":25,"name":26,"description":22,"armGroupLabels":27,"otherNames":11},"DRUG","CHX 0.12%",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Andrea Pilloni, Professor","CONTACT","+39-0649-918152","andrea.pilloni@uniroma1.it",[35],{"facility":36,"status":11,"city":37,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Sapienza University of Rome","Rome","00161","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],12.51133,41.89193,{"lat":45,"lon":44},[48,50],{"name":49,"role":31,"phone":11,"phoneExt":11,"email":33},"Andrea Pilloni",{"name":11,"role":31,"phone":32,"phoneExt":11,"email":11},{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Andrea Pilloni MD DDS MS","Professor","100572828","clinical-efficacy-of-a-chlorhexidine-based-mouth-rinse-containing-citrus-aurantium-amara-100572828",false,"NCT06738342","Clinical Efficacy of a Chlorhexidine-based Mouth-rinse Containing Citrus Aurantium Amara","Clinical Efficacy of a Chlorhexidine-based Mouth-rinse Containing Citrus Aurantium Amara in Patients Undergoing Periodontal Surgery: a Triple-blind, Parallel-arm, Randomized Controlled Trial","CUR_01","Inclusion Criteria:\n\n* More than 20 natural teeth excluding the third molars\n* Clinical indication for a surgical intervention for the treatment of at least one residual pocket after non-surgical therapy (pocket depth (PD) ≥5mm)\n* Have a full mouth plaque score (FMPS) \\\u003C15% before surgery;\n* Have a full mouth bleeding score (FMBS) \\\u003C15% before surgery;\n* Ability and willingness to give written informed consent;\n* Written agreement to participate in the trial.\n\nExclusion Criteria:\n\n* Use of medications, such as anti-platelet or anti-coagulant agents, any other concomitant systemic disorder, cardiovascular and diabetes diseases, allergic, infectious diseases and medications affecting periodontal inflammation\n* Pregnancy or breastfeeding;\n* Use of medication affecting the healing process;\n* Assumption of systemic or local antibiotics in the 4 weeks before trial beginning;\n* Conditions of the teeth or of the site that contraindicate the surgery (severe mobility, fractures, untreated endodontic lesions, incongruous restorations);\n* Patients with previous periodontal treatment or who were undergoing a course of dental or orthodontic treatment will be also excluded.\n* Tobacco use (10 or more cigarettes per day)\n* Inability to comply with protocol\n* Uncooperative patient",true,"ALL","18 Years","65 Years",{"count":68,"type":69},32,"ESTIMATED","INTERVENTIONAL",[72],"NA","The primary objective of the study is the evaluation of efficacy of a mouthwash cointaining Chlorexidine (CHX) 0.09% + HA + Citrox (test group) on the quality of wound healing and the presence plaque formation and gingival inflammation in the post-surgical phase. Futhermore stains, discolorations and adverse effects will be eventually recorded. Control group will be represented by the use of a CHX 0.12% mouthwash.",[75],"Wound Healing","NOT_YET_RECRUITING","2024-12-17",{"date":79,"type":80},"2024-12-20","ACTUAL",{"date":82,"type":69},"2024-12",{"date":84,"type":69},"2025-04",{"name":5,"class":6},1]